Search for drugs:
Typing the drug name to query
COBICISTAT
DIR Classification
Classification:Moderate-DIQT concern
Severity Score:3.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- DRUG INTERACTIONS
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a thorough QT/QTc study in 48 healthy subjects, a single dose of cobicistat 250 mg and 400 mg (1.67 and 2.67 times the dose in TYBOST) did not affect the QT/QTc interval. Prolongation of the PR interval was noted in subjects receiving cobicistat. The maximum mean (95% upper confidence bound) difference in PR from placebo after baseline-correction was 9.5 (12.1) msec for the 250 mg cobicistat dose and 20.2 (22.8) for the 400 mg cobicistat dose.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
4
24088
Other ADRs
10834
38370753
Odds Ratio = 0.589
Drug Property Information
ATC Code(s):
- V03AX03 - cobicistat
- V03AX - Other therapeutic products
- V03A - ALL OTHER THERAPEUTIC PRODUCTS
- V03 - ALL OTHER THERAPEUTIC PRODUCTS
- V - VARIOUS
Active Ingredient:COBICISTAT
Active Ingredient UNII:LW2E03M5PG
Drugbank ID:DB09065
PubChem Compound:25151504
CTD ID:D000069547
PharmGKB:PA166165092
CAS Number:1004316-88-4
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 150.0 mg/day V03AX03
Chemical Structure: 
SMILE Code:
CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Reference
1: Pharmacogenomics of COVID-19 therapies.
[Takahashi Takuto,Luzum Jasmine A,Nicol Melanie R,Jacobson Pamala A]NPJ Genom Med,2020 Aug 18;5:35. PMID: 32864162
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.